Insulin Human Inhalation Powder [19] |
Rapid on, rapid off mitigate postprandial hyperglycemia |
Hyperglycemia correction, prandial insulin dosing, patients with lipodystrophy or needle phobia |
Spirometry (FEV1) prior to use, then every 6–12 months, contraindicated in chronic lung disease & active lung cancer, caution use in those who smoke, severe hypoglycemia |
Bronchospasm, hypoglycemia, throat pain/irritation |
Fast-acting insulin aspart [11,12,13] |
Rapid on, rapid off |
Hyperglycemia correction, prandial insulin dosing, may be given within 20 minutes of the start of a meal |
Severe hypoglycemia |
Hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, weight gain |
Glargine U300 [25] |
Duration of action > 24 hours, can be given at any time during the day rather than the same time each day |
Patients who have difficulty remembering to take insulin at the same time each day |
Titrate dose no more frequently than every 3–4 days to minimize risk of hypoglycemia, a higher daily dose may be needed than Glargine U100 insulin |
Hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritis, rash edema, weight gain |
Degludec [30] |
Duration of action > 24 hours, can be given at any time during the day rather than the same time each day, pediatric patients |
Patients who have difficulty remembering to take insulin at the same time each day, those needing greater than 80 units of basal insulin each day (up to 160 units in a single dose), those who experience pain with insulin injections (physiologic pH) |
Titrate doses no more frequently than every 3–4 days to minimize risk of hypoglycemia, doses should be given no less than 8 hours apart, no conversion needed between U100 and U200 insulins |
Hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritis, rash, edema, weight gain |